55304-85-3

Usage

Uses

Used in Organic Synthesis:
2,6-Dibromo-3-pyridinecarboxylic acid is used as a key intermediate in organic synthesis for the production of various pharmaceuticals and agrochemicals. Its high reactivity allows it to participate in cross-coupling reactions and other organic transformations, facilitating the creation of a diverse range of chemical compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,6-Dibromo-3-pyridinecarboxylic acid is used as a building block for the development of new drugs. Its unique structure and reactivity make it a promising candidate for the synthesis of therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Industry:
2,6-Dibromo-3-pyridinecarboxylic acid is also utilized in the agrochemical industry as an intermediate for the synthesis of pesticides and other crop protection agents. Its ability to form stable and effective compounds makes it a valuable component in the development of innovative and environmentally friendly agrochemical products.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2,6-Dibromo-3-pyridinecarboxylic acid is employed for drug discovery and development. Its unique chemical properties and potential to form a wide range of compounds make it an attractive starting material for the design and synthesis of novel therapeutic agents with improved efficacy and selectivity.
Overall, 2,6-Dibromo-3-pyridinecarboxylic acid is a versatile and valuable chemical compound with diverse applications across various industries, particularly in the development of pharmaceuticals, agrochemicals, and other organic compounds. Its high reactivity and potential for cross-coupling reactions make it an essential component in the synthesis of innovative and effective products.

InChI:InChI=1/C6H3Br2NO2/c7-4-2-1-3(6(10)11)5(8)9-4/h1-2H,(H,10,11)

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 124-38-9 carbon dioxide 
• 55304-83-1 2,6-dibromo-pyridine-3-carbaldehyde 

Downstream Products

• 1009735-22-1 methyl 2,6-dibromopyridine-3-carboxylate 

Relevant academic research and scientific papers

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

BICYCLIC INHIBITORS OF ANAPHASTIC LYMPHOMA KINASE

Disclosed are compounds of formula (Ⅰ) and their pharmaceutical acceptable salts, wherein R1, R2, R3, X, Y, Z, A, B, G1, m and n are defined in the description. The compositions containing the said compounds used for inhibiting kinases such as anaphastic lymphoma kinase (ALK) and methods of treating diseases such as cancer are disclosed.

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

Continuous process for the production of polybromopyridine compounds

A continuous process for producing a polybromopyridine compound comprises admixing a polychloropyridine compound with an anhydrous water soluble solvent in a first reaction zone to form a solution of the polychloropyridine compound. Hydrogen bromide gas is introduced into the solution while maintaining the temperature in the range of from about 70° to about 140° C. to produce a solution of the polybromopyridine compound. The solution is cooled to a temperature in the range of from about 5° to about 35° C. to precipitate the polybromopyridine compound from the anhydrous solvent. The polybromopyridine compound is separated from the anhydrous solvent and the anhydrous solvent is returned to the first reaction zone. Polybromopyridine compounds of increased purity are produced in a process having reduced material, energy and operating costs. The process does not require the use of water or other co-solvents nor the distillation of the reaction product mixture.